parkinsons-2016_scientifictracks-abstracts

4 / 20

Notes:
Page 27
Parkinsons 2016
December 05-07, 2016
Volume 6 Issue 6(Suppl) J Alzheimers Dis Parkinsonism
ISSN: 2161-0460 JADP, an open access journal
conferenceseries .com
December 05-07, 2016 Phoenix, USA
2nd International Conference on
Parkinson’s Disease & Movement Disorders
Charlene Aldrich, J Alzheimers Dis Parkinsonism 2016, 6:6(Suppl)
Clinical trials using MRI guided focused ultrasound (ExAblate Transcranial System) for the
management of medically-refractory dyskinesia symptoms of advanced idiopathic Parkinson’s
disease and in patients with benign essential tremors
Charlene Aldrich
University of Maryland, USA
The UMD is participating in collaborative studies for treatment of ET and PD. MRI guided focused ultrasound (MRgFUS)
is an attractive modality for non-invasive, thermal ablation of soft tissue and brain. This novel technology utilizes the
combination of diagnostic imaging with high-intensity focused ultrasound. It concentrates energy from a source outside of
the body on a small target-for PD and ET deep inside the brain. “Think sun–magnifying glass–leaf ” PD and ET are caused by
dysfunction of a circuit and system imbalance caused by functioning parallel circuits. Interruption of a specific parallel circuit
using FUS rebalances the system, reducing symptoms (tremor/rigidity). Historical FUS lacked necessary precision; today
precision have been overcome by coupling FUS to MRI simultaneous imaging of the target and the applied energy. The studies
are designed as prospective, multi-center, single-arm feasibility studies to evaluate the safety and initial clinical effectiveness
of ExAblate Transcranial unilateral thermal ablation of the globus pallidus of subjects suffering from medication-refractory
advanced idiopathic PD. To Evaluate the Effectiveness and Safety of ExAblate Transcranial MRgFUS Thalamotomy Treatment
of Medication Refractory Essential Tremor Subjects, Subjects age 30 and older with confirmed medication-refractory, advanced
idiopathic Parkinson’s disease or benign essential tremors are eligible for these studies.
Biography
Charlene Aldrich has a Master’s degree in Nursing and has been involved in clinical trials in neuroscience for 25 years. She is the Clinical Research Manager in
the Department of Neurosurgery and manages on an average 10 trials ranging from device trials to drug trials. Typical trials are multi-center national/international,
prospective and are Federal or industry funded. She initiates and maintains all trials regulatory and clinical conduct for the respective principal investigators in the
Department of Neurosurgery.